226922-92-5

Basic information

• Product Name: 6-BROMO-3,4-DIHYDRO-2,2-DIMETHYL-2H-CHROMEN-4-AMINE HCL
• Synonyms: 6-BROMO-3,4-DIHYDRO-2,2-DIMETHYL-2H-CHROMEN-4-AMINE HCL;6-broMo-3,4-dihydro-2,2-diMethyl-2H-chroMen-4-aMine hydrochloride;6-BroMo-2,2-diMethylchroMan-4-aMine;6-broMo-3,4-dihydro-2,2-diMethyl-2H-1-Benzopyran-4-aMine;6-Bromo-3,4-dihydro-2,2-dimethyl-2H-chroman-4-amine hydrochloride;6-broMo-2,2-diMethyl-chroMan-4-aMine hydrochloride
• CAS NO: 226922-92-5
• Molecular Formula: C₁₁H₁₄BrNO
• Molecular Weight: 292.61
• Mol File: 226922-92-5.mol

Chemical Properties

• Boiling Point: 327.2°C at 760 mmHg
• Flash Point: 151.7°C
• Appearance: /
• Density: 1.351
• Vapor Pressure: 0.000149mmHg at 25°C
• CAS DataBase Reference: 6-BROMO-3,4-DIHYDRO-2,2-DIMETHYL-2H-CHROMEN-4-AMINE HCL(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-3,4-DIHYDRO-2,2-DIMETHYL-2H-CHROMEN-4-AMINE HCL(226922-92-5)
• EPA Substance Registry System: 6-BROMO-3,4-DIHYDRO-2,2-DIMETHYL-2H-CHROMEN-4-AMINE HCL(226922-92-5)

Safety Data

• Hazardous Substances Data: 226922-92-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-BROMO-3,4-DIHYDRO-2,2-DIMETHYL-2H-CHROMEN-4-AMINE HCL is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structural features may contribute to the development of new drugs with specific therapeutic properties.
Used in Chemical Industry:
In the chemical industry, 6-BROMO-3,4-DIHYDRO-2,2-DIMETHYL-2H-CHROMEN-4-AMINE HCL may be utilized as a building block or a precursor in the synthesis of other organic compounds. Its bromo group can be a key functional group for further chemical reactions and modifications.

InChI:InChI=1/C11H14BrNO.ClH/c1-11(2)6-9(13)8-5-7(12)3-4-10(8)14-11;/h3-5,9H,6,13H2,1-2H3;1H

Upstream product

• 99853-21-1 6-bromo-2,2-dimethylchroman-4-one 
• 106-41-2 4-bromo-phenol 
• 1927-95-3 4-bromophenyl acetate 
• 1450-75-5 5-Bromo-2-hydroxyacetophenone 
• 131815-91-3 (R/S)-6-bromo-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-ol 
• 226922-87-8 4-(N-acetylamino)-6-bromo-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran 

Downstream Products

• 226922-97-0 6-bromo-3,4-dihydro-2,2-dimethyl-4-(4-methylbenzenesulphonylaminocarbonylamino)-2H-1-benzopyran 
• 226922-98-1 6-bromo-4-(4-chlorobenzenesulphonylaminocarbonylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran 
• 226922-96-9 4-(benzenesulphonylaminocarbonylamino)-6-bromo-2,2-dimethyl-3,4-dihydro-2H-1-benzopyran 

Relevant articles and documents

MACROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AS BACE INHIBITORS

The invention relates to novel macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms include

4,6-Disubstituted 2,2-dimethylchromans structurally related to the K ATP channel opener cromakalim: Design, synthesis, and effect on insulin release and vascular tone

Five series (ureas, thioureas, carbamates, sulfonylureas, and amides) of 4,6-disubstituted-2,2-dimethylchromans structurally related to cromakalim were prepared and evaluated, as putative ATP-sensitive potassium channel activators, on rat pancreatic islets and rat aorta rings. The biological data indicate that most compounds were, like the reference molecule cromakalim, more active on the vascular smooth muscle tissue (myorelaxant effect on 30 mM KCl induced contractions of rat aorta rings) than on the pancreatic tissue (inhibition of 16.7 mM glucose induced insulin release from rat pancreatic islets). However, some drugs (8h, 8i, 9f, 9g, 9h, and 9i) markedly inhibited insulin release and exhibited an activity equivalent or greater than that of diazoxide. Compounds 9h and 9i were also found to be more active on pancreatic β-cells than on vascular smooth muscle cells. Last, the amide 6b was selected in order to examine its mechanism of action on vascular smooth muscle cells. Pharmacological results suggest that the compound acted as a KATP channel opener. In conclusion, the present data indicate that appropriate structural modifications can generate dimethylchromans with pharmacological profiles different from that of cromakalim.

Synthesis and pharmacological evaluation of K(ATP)-channel openers related to cromakalim: Introduction of arylsulphonylurea moieties

A series of 4-(arylsulphonylaminocarbonylamino)-3,4-dihydro-2,2-dimethyl-2 H-1-benzopyran derivatives were prepared and evaluated as potential ATP-sensitive potassium-channel activators. Pharmacological studies showed that some compounds expressed vasodilator efficacy on vascular smooth muscle. The compounds had no inhibitory activity on insulin secretion from pancreatic β-cells.